Clene (NASDAQ:CLNN) (NASDAQ: CLNN) is a clinical-stage biotechnology company focused on developing novel nanomedicines to treat neurodegenerative and neuroinflammatory disorders. The company’s core technology platform centers on a proprietary gold nanocrystal therapeutic, known as CNM-Au8, which is designed to enhance cellular energy production and provide antioxidant protection. Clene’s primary development programs target conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease, with multiple clinical trials underway to evaluate safety and efficacy in these patient populations.
CNM-Au8 leverages catalytic nanotechnology to support cellular bioenergetics and reduce oxidative stress, mechanisms implicated in the progression of neurodegeneration. In addition to its lead program for ALS, Clene is advancing clinical studies in relapsing-remitting MS and Parkinson’s disease, and is exploring broader applications of its platform in other neurological indications. The company’s research and manufacturing operations are supported by partnerships with academic institutions and specialized contract development and manufacturing organizations (CDMOs).
Founded in 2014 and headquartered in Salt Lake City, Utah, Clene maintains research collaborations and regulatory engagement across North America, Europe and Australia. The company went public on the Nasdaq in 2020, positioning itself to expand clinical development and scale the manufacturing of its nanocatalyst technology. Clene’s regulatory strategy has included obtaining orphan drug designations and fast-track status from the U.S. Food and Drug Administration to expedite development in rare neurodegenerative disorders.
Clene’s leadership team comprises experienced professionals in biotechnology research, clinical development, regulatory affairs and finance. Guided by a board of directors with deep expertise in neuroscience and pharmaceuticals, the company continues to advance its pipeline through collaborative research efforts, strategic partnerships and ongoing engagement with patient advocacy groups. Clene aims to transform the treatment paradigm for debilitating neurological diseases by harnessing the potential of nanomedicine.
